Glycorex Transplantation
1,795
SEK
-4,52 %
GTAB B
NGM Main Regulated
Biotechnology & Pharmaceuticals
Health Care
Vær den første som følger denne virksomhed
-4,52%
+24,65%
+23,79%
+90,55%
+35,47%
+15,81%
-80,78%
-81,46%
-82,32%
glycorex.com
Glycorex Transplantation is a biotechnology company. The company conducts research, development, and marketing within the field of organ transplantation. The main product of the company, Glycosorb-ABO, enables transplants irrespective of the blood type of the donors and the recipients. Transplants with the help of the company's product have been carried out worldwide. Glycorex Transplantation was founded in 1996 and is based in Lund.
Omsætning
29,96 mio.
EBIT %
-101,07 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NGM Main Regulated
GTAB B
Daglig lav / høj pris
1,72 / 1,875
SEK
Markedsværdi
132,57 mio. SEK
Aktieomsætning
76,33 t SEK
Volumen
43 t
Større aktionærerKilde: Millistream Market Data AB
| Ejer | Kapital | Stemmer |
|---|---|---|
| Avanza Pension | 10,9 % | 7,8 % |
| Wendt Investment AB | 7,1 % | 5,1 % |
| Glycorex AB | 6,7 % | 17,0 % |
| Nilsson, Kurt med maka och bolag | 3,1 % | 18,5 % |
| Henningson Affärsfastigheter AB | 3,0 % | 2,1 % |
| Nordnet pensionsförsäkring AB | 3,0 % | 2,1 % |
| Wendt Cecilia | 2,0 % | 1,5 % |
| Skandia Försäkrings AB | 1,9 % | 1,9 % |
| Bill Nederman | 1,7 % | 1,2 % |
| Richard Hansson | 1,5 % | 1,1 % |
ViserAlle indholdstyper
Glycorex Transplantation AB: First ABO-incompatible transplantation in Argentina with Glycosorb® ABO
Glycorex Transplantation: Glycosorb® ABO is pushing the boundaries in paediatric blood group incompatible heart transplantation
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools